Alpa Labs Approves Q3 FY26 Unaudited Standalone & Consolidated Financial Results
Alpa Laboratories Limited's Board approved Q3 FY26 unaudited standalone and consolidated financial results. For the quarter ended December 31, 2025, standalone revenue from operations stood at ₹29.67 crore, and consolidated revenue from operations was ₹29.05 crore. Standalone and consolidated EPS for the quarter were ₹0.89 and ₹0.90, respectively.
The approval of quarterly financial results is a material event for investors and stakeholders, providing insights into the company's performance. This information can influence investment decisions.
The announcement reports the approval of financial results, which is a routine disclosure. While the results themselves might have specific performance indicators, the announcement itself is factual and does not contain overtly positive or negative language.
Alpa Laboratories Limited announced the outcome of its Board Meeting held on February 11, 2026, at 11:00 AM at the company's registered office. The Board of Directors approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2025, along with the Limited Review Report from the Statutory Auditors.
The meeting commenced at 11:00 AM and concluded at 12:05 PM. The financial results for the quarter ended December 31, 2025, show standalone revenue from operations at ₹29.67 crore and consolidated revenue from operations at ₹29.05 crore.
For the nine months ended December 31, 2025, standalone revenue from operations was ₹74.41 crore, and consolidated revenue from operations was ₹74.41 crore. The basic and diluted earnings per share (EPS) for the quarter ended December 31, 2025, were ₹0.89 on a standalone basis and ₹0.90 on a consolidated basis.
What to do with a filing like this
Alpa Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alpa Laboratories Limited. Read the original for the full detail.